/PRNewswire/ -- AnX Robotica, a leader in advanced gastrointestinal diagnostic solutions, is proud to announce the FDA 510(k) clearance of MotiliCap™ and its companion software, MotiliScan™. This latest clearance marks a significant step forward in GI motility monitoring, offering clinicians an advanced, non-invasive tool for assessing whole-gut transit times with unmatched accuracy and patient comfort..

/PRNewswire/ -- 作为先进胃肠诊断解决方案的领导者，安X机器人公司自豪地宣布，MotiliCap™及其配套软件MotiliScan™已获得FDA 510(k)许可。这一最新的许可标志着胃肠道动力监测的重大进步，为临床医生提供了一种先进的、非侵入性的工具，能够以无与伦比的精确性和患者舒适度评估全肠道传输时间。

MotiliCap™ is a next-generation motility capsule designed to evaluate gastrointestinal transit across the stomach, small bowel, and colon. As the most comprehensive solution available, MotiliCap replaces the discontinued SmartPill™ technology, delivering detailed insights into gastric emptying, small bowel transit, and colonic motility—all without radiation or sedation.

MotiliCap™ 是一种下一代运动胶囊，旨在评估胃、小肠和结肠的胃肠道传输。作为目前最全面的解决方案，MotiliCap 取代了已停产的 SmartPill™ 技术，提供有关胃排空、小肠传输和结肠蠕动的详细信息——且无需辐射或镇静。

Data is seamlessly exported to the MotiliScan™ software, where clinicians can visualize pH, pressure, and temperature changes, offering a complete view of GI motility..

数据无缝导出到MotiliScan™软件，临床医生可以在其中可视化pH值、压力和温度变化，提供胃肠道动力的完整视图。

'We are thrilled to receive FDA clearance for MotiliCap and MotiliScan, reinforcing our commitment to bringing innovative, patient-friendly diagnostic tools to patients and our customers,'

“我们非常高兴获得FDA对MotiliCap和MotiliScan的批准，这进一步巩固了我们为患者和客户带来创新、便捷的诊断工具的承诺。”

said

说

Stu Wildhorn

斯图·维尔德霍恩

, Vice President of Marketing and Product Management at AnX Robotica.

AnX Robotica市场营销和产品管理副总裁。

'MotiliCap not only fills the void left by SmartPill but enhances it with the latest technologies, customer friendly ease of use and analysis capabilities, empowering clinicians with faster, more accurate diagnostic insights.'

“MotiliCap不仅填补了SmartPill留下的空白，还通过最新技术、用户友好的操作和分析能力对其进行了增强，使临床医生能够获得更快速、更准确的诊断洞察。”

The MotiliScan™ software provides intuitive visualization and seamless data analysis, enabling physicians to identify motility disorders and expedite treatment decisions. Designed with both efficiency and precision in mind, MotiliScan allows for customizable reporting, segment-specific analysis, and automated summaries—supporting improved clinical workflows and better patient outcomes..

MotiliScan™ 软件提供直观的可视化和无缝的数据分析，帮助医生识别运动障碍并加速治疗决策。MotiliScan 以效率和精确性为核心设计，支持可定制报告、特定节段分析和自动生成摘要，有助于优化临床工作流程并改善患者预后。

With this FDA clearance, AnX Robotica continues its mission to revolutionize patient care with advanced GI technologies, building on the success of the NaviCam

随着这项FDA认证的通过，安X机器人公司继续其通过先进的胃肠技术革新患者护理的使命，建立在NaviCam的成功基础之上。